Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion
The German pharmaceutical-and-agricultural group said the acquisition would complement its drug pipeline and leverage its ophthalmology footprint.
Connecting Global Economies
The German pharmaceutical-and-agricultural group said the acquisition would complement its drug pipeline and leverage its ophthalmology footprint.